Welcome to our latest edition, where we spotlight Novo Nordisk A/S (NOVO-B.CO). In this detailed analysis, you’ll discover Novo’s key growth driver, GLP-1, understand its significance, and explore the future prospects of its groundbreaking medications. As always, we’ll dive into the company’s history, evaluate recent performance, assess dividend safety, and determine its fair value (which may align with your desired return).

Additionally, we’ll provide a brief insight into Greggs Plc (GRG.L), a UK-based fast-food chain. With the general undervaluation of European stocks compared to their US counterparts, could there still be an opportunity to acquire them at an attractive valuation? Join us as we uncover the potential of these intriguing companies.

If you are new to this newsletter and would like to give it a try, then check out the first 3 newsletters for free:
1. A deep dive into L’Oreal | Newsletter #001
2. A deep dive into British American Tobacco | Newsletter #002
3. A deep dive into NN Group – is their Dividend Safe? | Newsletter #003

What you can expect in this issue:

• A deep dive into Novo Nordisk?
• A look into UK dividend Growth Stock Greggs.
• New stock cards such as CCOI, SYY, and IPAR are also available.
• Our watchlist and most recent transactions.
• News of the week with Aholds delhaize and HPQ

Yours Truly,

European Dividend Growth Investor & Derek from Dividend Talk.

Premium subscribers can download the newsletter below (after login) 👇

<< Download Newsletter by Clicking here >>>